Publication date: Aug 01, 2026
Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic altered the circulation of respiratory pathogens. Following an initial decline in infections, a resurgence occurred as restrictions eased. We aimed to determine whether reduced early-life exposure to pathogens increased the risk of severe respiratory infections. In this longitudinal nationwide population-based study in Sweden, we compared a pandemic birth cohort of children born in Sweden between March 1 and December 31 from 2020 (n = 92,791) with aligned pre-pandemic cohorts born between 1 March and December 31 of 2015 (n = 94,552) and of 2018 (n = 96,074). Children with missing covariate data, death, or emigration before the age of two were excluded (10.5%). Baseline characteristics for the first two years of life were summarized. Outcomes were assessed between ages 2-4 years. Hospitalization for overall and specific lower respiratory tract infections (LRTI) was analysed as a binary outcome using logistic regression. Children born in 2020 had markedly lower hospitalisation rates during their first two years of life than both pre-pandemic cohorts. However, between ages 2 and 4, they exhibited significantly higher hospitalisation risk compared with both pre-pandemic cohorts. Adjusted odds ratio (aOR) for hospitalisation in the 2020 versus 2015 cohort were: all-cause LRTI (2.51 (95% CI 2.26-2.79)), influenza (2.99, 2.38-3.79) and respiratory syncytial virus (RSV) (4.36, 3.60-5.31). Similar patterns were observed for all-cause pneumonia and mycoplasma. The 2018 cohort showed a more mixed pattern, with lower risk for pneumonia but higher risk for RSV. Children born during the COVID-19 pandemic initially had a reduced risk of hospitalisation for respiratory infections, followed by a substantially increased risk in the post-pandemic period compared to children born before the pandemic. These findings suggest that altered early-life microbial exposure due to pandemic-related restrictions may influence subsequent patterns of severe childhood infections through immunological or exposure-related mechanisms and emphasis the need for further research to elucidate underlying mechanisms. The SCIFI-PEARLS project has basic fundings from the Swedish government and the county councils, the ALF agreement, the Swedish Research Council for Health, Working Life and Welfare, (Forte), and previously a joint grant from Forte-and the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (Formas).
Open Access PDF
| Concepts | Keywords |
|---|---|
| Child health | |
| COVID-19 | |
| Immune debt | |
| Non-pharmaceutical interventions | |
| Respiratory infections |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | respiratory infections |
| disease | MESH | COVID-19 pandemic |
| disease | MESH | infections |
| disease | MESH | death |
| disease | MESH | influenza |
| disease | MESH | pneumonia |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | infectious diseases |
| disease | MESH | strain |
| disease | MESH | pertussis |
| pathway | KEGG | Pertussis |
| drug | DRUGBANK | Isoxaflutole |
| disease | MESH | SCFI |
| drug | DRUGBANK | Pearl (hyriopsis cumingii) |
| disease | MESH | birth weight |
| disease | MESH | respiratory syncytial virus infection |
| disease | MESH | included |
| disease | MESH | pyothorax |
| disease | MESH | pneumococcal infection |
| disease | MESH | ICD |
| disease | MESH | dar |
| disease | MESH | asthma |
| pathway | KEGG | Asthma |
| disease | MESH | palsy |
| disease | MESH | bronchopulmonary dysplasia |
| disease | MESH | chromosomal abnormalities |
| disease | MESH | bacterial pneumonia |
| disease | MESH | mycoplasma infection |
| disease | MESH | viral infections |